ロード中...
Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
Tyrosine kinase inhibitors (TKIs) have dramatically improved the life expectancy of patients suffering from chronic myeloid leukemia (CML); however, patients will eventually develop resistance to TKI therapy or adverse side effects due to secondary off-target mechanisms associated with TKIs. CML pat...
保存先:
| 出版年: | Tumour Biol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Netherlands
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5080333/ https://ncbi.nlm.nih.gov/pubmed/27444277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13277-016-5179-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|